Delaloye AB - Search Results

1

Longer intervals between hematopoietic stem cell transplantation and subsequent 90Y-ibritumomab radioimmunotherapy may correlate with better tolerance.

Buchegger F, Prior JO, Allenbach G, Baechler S, Kosinski M, Helg C, Chalandon Y, Ratib O, Delaloye AB, Ketterer N. Buchegger F, et al. Among authors: delaloye ab. Clin Nucl Med. 2012 Oct;37(10):960-4. doi: 10.1097/RLU.0b013e318251e3af. Clin Nucl Med. 2012. PMID: 22955069

2

Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission.

Buchegger F, Antonescu C, Helg C, Kosinski M, Prior JO, Delaloye AB, Press OW, Ketterer N. Buchegger F, et al. Among authors: delaloye ab. J Nucl Med. 2011 Jun;52(6):896-900. doi: 10.2967/jnumed.111.087460. Epub 2011 May 13. J Nucl Med. 2011. PMID: 21571800 Free article.

3

Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma.

Buchegger F, Antonescu C, Delaloye AB, Helg C, Kovacsovics T, Kosinski M, Mach JP, Ketterer N. Buchegger F, et al. Among authors: delaloye ab. Br J Cancer. 2006 Jun 19;94(12):1770-6. doi: 10.1038/sj.bjc.6603166. Epub 2006 May 9. Br J Cancer. 2006. PMID: 16685263 Free PMC article. Clinical Trial.

4

Lymphoscintigraphy in a patient with polyserositis of unknown origin.

Prior JO, Boubaker A, Spertini F, Delaloye AB. Prior JO, et al. Among authors: delaloye ab. Clin Nucl Med. 2002 Dec;27(12):905-6. doi: 10.1097/00003072-200212000-00019. Clin Nucl Med. 2002. PMID: 12607880 No abstract available.

5

Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after 90 Y-ibritumomab-tiuxetan.

Cicone F, Russo E, Carpaneto A, Prior JO, Delaloye AB, Scopinaro F, Ketterer N. Cicone F, et al. Among authors: delaloye ab. Hematol Oncol. 2011 Sep;29(3):131-8. doi: 10.1002/hon.968. Epub 2010 Sep 22. Hematol Oncol. 2011. PMID: 20862654

6

The preparation of clinical grade 5-[123I]iodo-2'-deoxyuridine and 5-[125I]iodo-2'-deoxyuridine with high in vitro stability and the potential for early proliferation scintigraphy.

Schaffland AO, Delaloye AB, Kosinski M, Dupertuis YM, Buchegger F. Schaffland AO, et al. Among authors: delaloye ab. Nucl Med Commun. 2004 May;25(5):461-8. doi: 10.1097/00006231-200405000-00006. Nucl Med Commun. 2004. PMID: 15100504

7

131I-rituximab: relationship between immunoreactivity and specific activity.

Schaffland AO, Buchegger F, Kosinski M, Antonescu C, Paschoud C, Grannavel C, Pellikka R, Delaloye AB. Schaffland AO, et al. Among authors: delaloye ab. J Nucl Med. 2004 Oct;45(10):1784-90. J Nucl Med. 2004. PMID: 15471849 Free article.

8

Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma.

Buchegger F, Press OW, Delaloye AB, Ketterer N. Buchegger F, et al. Among authors: delaloye ab. Oncologist. 2008 Jun;13(6):657-67. doi: 10.1634/theoncologist.2008-0020. Oncologist. 2008. PMID: 18586921 Free article. Review.

9

Suppressing bladder artifacts in bone SPECT of the pelvis.

Allenbach G, Prior JO, Theumann N, El-Hasnawy N, Malterre J, Delaloye AB, Kamel EM. Allenbach G, et al. Among authors: delaloye ab. Ann Nucl Med. 2007 Aug;21(6):339-44. doi: 10.1007/s12149-007-0036-9. Epub 2007 Aug 27. Ann Nucl Med. 2007. PMID: 17705013 Clinical Trial.

10

Bellini duct carcinoma: visualization on F-18 FDG PET/CT.

Marx K, Bauer J, Guillou L, Delaloye AB, Prior J. Marx K, et al. Among authors: delaloye ab. Clin Nucl Med. 2009 Aug;34(8):541-2. doi: 10.1097/RLU.0b013e3181abb768. Clin Nucl Med. 2009. PMID: 19617742 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

63 results

Search Page